scholarly journals Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia

2021 ◽  
Vol 56 (3) ◽  
pp. 178
Author(s):  
Ahmad Nugroho ◽  
Johan Renaldo ◽  
Wahjoe Djatisoesanto
Keyword(s):  
Side Effects ◽  
Tumor Marker ◽  
Complete Blood Count ◽  
Early Stage ◽  
Tumor Staging ◽  
Serum Levels ◽  
Chemotherapy Response ◽  
Serum Tumor Marker ◽  
Regional Lymph Nodes ◽  
Response To Chemotherapy

The purpose of this study to describe patientscharacteristics, correlation between stagingnon-seminomacancer and chemotherapyresponse. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records inSoetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapyresponse, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N) and metastasis (M), correlation serum tumor marker and chemotherapy response was proccessed by Spearman correlation test. There were no significant correlation between pT staging and M and no significant correlation between N and M staging. Based on tumor markers (S), mostly patients were S2. There were no significant correlation between the response to chemotherapy and serum tumor marker levels. In category of staging group, the mostare 14 patientsstage III. BEP was the most adjuvant Chemotherapy.Nausea and vomiting were The most complained during chemotherapy. Anemia were the most hematologic side effects of chemotherapy.There are no significant correlation between the staging of non-seminoma and the response to chemotherapy. Conclusion: Non seminoma mostly happened in young males. Non-seminoma responses to chemotherapy. Patients in early stage would give a good response to chemotherapy compared to those with advanced stage. After chemotherapy, evaluation should be done to the patients' complaints and complete blood count to detect side effects.

scholarly journals Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia

2020 ◽  
Vol 56 (3) ◽  
pp. 178
Author(s):  
Achmad Nugroho ◽  
Johan Renaldo ◽  
Wahjoe Djatisoesanto
Keyword(s):  
Side Effects ◽  
Tumor Marker ◽  
Complete Blood Count ◽  
Early Stage ◽  
Tumor Staging ◽  
Serum Levels ◽  
Chemotherapy Response ◽  
Serum Tumor Marker ◽  
Regional Lymph Nodes ◽  
Response To Chemotherapy

The purpose of this study was to describe patients’ characteristics, correlation between staging non-seminoma cancer and chemotherapy response. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records in Soetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapy response, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N) and metastasis (M), correlation serum tumor marker and chemotherapy response was proccessed by Spearman correlation test. There were no significant correlation between pT staging and M and no significant correlation between N and M staging. Based on tumor markers (S), mostly patients were S2. There were no significant correlation between the response to chemotherapy and serum tumor marker levels. In category of staging group, the most are 14 patients stage III. BEP was the most adjuvant Chemotherapy. Nausea and vomiting were The most complained during chemotherapy. Anemia were the most hematologic side effects of chemotherapy. There are no significant correlation between the staging of non-seminoma and the response to chemotherapy. Conclusion: Non seminoma mostly happened in young males. Non-seminoma responses to chemotherapy. Patients in early stage would give a good response to chemotherapy compared to those with advanced stage. After chemotherapy, evaluation should be done to the patients' complaints and complete blood count to detect side effects. 

scholarly journals Testicular Seminoma: Correlation Between Staging and Chemotherapy Response, Two Years Overall Survival Rate

2019 ◽  
Vol 3 (1) ◽  
pp. 24
Author(s):  
Ida Bagus Putra Pramana ◽  
Lukman Hakim ◽  
Wahjoe Djatisoesanto ◽  
Sunaryo Hardjowijoto
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Early Stage ◽  
Tumor Staging ◽  
Previous History ◽  
Stage I ◽  
Chemotherapy Response ◽  
Overall Survival Rate ◽  
Testicular Seminoma ◽  
Response To Chemotherapy

Objective: to determine the patient’s characteristics, correlation between staging and chemotherapy response, furthermore two years overall survival rate. Methods: a retrospective analytic study was conducted. Data were obtained from medical records in January 2008 to December 2014 and analyzed using SPSS 17.0. All of correlation between staging and chemotherapy response, primary tumor staging (pT) and metastasis (M), regional lymph nodes staging (N) and metastasis (M), serum tumor marker and chemotherapy response were tested by Spearman correlation test. Two years overall survival rate was analyzed by Kaplan-Meier. Data ratio with normal distribution was tested by Paired T-test. Results: the mean age of patients were 31.03 ± 13.751 years, with seven patients (15.6%) had previous history of undescended testis. Based on TNM staging, we found that most patients had already develop into stage pT3 (46.7%), N3 (57.7%), and M0 (57.7%). A significant correlation between staging and chemotherapy response was shown with stage I of testicular seminoma had completely chemotherapy response (100%) and two years overall survival rate in stage I was 100%, whereas in metastatic seminoma (stage II and III) was 60%, with Hazard Ratio 0.63 (p=0.294; 95%CI 0.276-1.476). Conclusion: patients in early stage of testicular seminoma will give a better response to chemotherapy and will have better survival rate compared to those with metastatic seminoma.

Assessment of Relationship Between CT Features and Serum Tumor Marker Index in Early-stage Lung Adenocarcinoma

2016 ◽  
Vol 23 (11) ◽  
pp. 1342-1348 ◽  
Author(s):  
Yanyan Xu ◽  
Hongliang Sun ◽  
Zhenrong Zhang ◽  
Aiping Song ◽  
Wu Wang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Tumor Marker ◽  
Early Stage ◽  
Serum Tumor Marker ◽  
Marker Index ◽  
Ct Features

Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 654-654
Author(s):  
Toshiyasu Watanabe ◽  
Eiji Shinozaki ◽  
Sho Kijima ◽  
Yoshihito Ohhara ◽  
Yasutoshi Kuboki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Clinical Benefit ◽  
Chemotherapy Response ◽  
Chimeric Mouse ◽  
Serum Tumor Marker ◽  
Wild Type ◽  
Tumor Marker Level ◽  
Marker Level

654 Background: Panitumumab and cetuximab can be used in metastatic colorectal cancer (mCRC) and these drugs are IgG2 fully human and IgG1 chimeric (mouse/human) monoclonal antibody against the epidermal growth hactor receptor (EGFR) respectively. The efficacy of panitumumab as a salvage chemotherapy after cetuximab-based chemotherapy failure is not clarified. Methods: This study aimed to evaluate the panitumumab efficacy to KRAS wild-type mCRC patients who failed cetuximab-based chemotherapy. Response, progression-free survival (PFS) and serum tumor marker level (CEA and CA19-9), were assesed. We studied response by days from last cetuximab-based chemotherapy to panitumumab induction (C-P days). Results: 22 patients (11 men, 11 women, median age 54 years m4 0-78 n) were enrolled. All of thease patients were cetuximab-based chemotherapy refractory KRAS wild-type mCRC. After progression, they received panitumumab monotherapy (6 mg/kg every 2 weeks).The best response was SD 10/22 (45.5%), PD 11/22 (50%) and NE 1/22 (4.5%). Overall median PFS was 90 days (13 to 182). The patients C-P days less than 30 days were 15 patients(5:SD, 10:PD). The patients more than 79 days were 7 patient(5:SD, 1:PD, 1:NE). Serum tumor marker level was decreased more than 50% patients. Conclusions: This study suggested that it might be limited as possibility of clinical benefit with panitumumab administration after cetuximab failure.

scholarly journals Recognizing and managing on toxicities in cancer immunotherapy

Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769454 ◽  
Author(s):  
Liu Yang ◽  
Huifang Yu ◽  
Shuang Dong ◽  
Yi Zhong ◽  
Sheng Hu
Keyword(s):  
Side Effects ◽  
Cancer Immunotherapy ◽  
Complete Blood Count ◽  
Early Stage ◽  
Maculopapular Rash ◽  
Therapeutic Agents ◽  
High Dose ◽  
The Past ◽  
Routine Monitoring ◽  
Different Types

Over the past 4 years, cancer immunotherapy has significantly prolonged survival time of patients with prostate cancer, melanoma, lung cancer, and liver cancer, but its side effects are also impressive. Different types of the immune therapeutic agents have different on-target or off-target toxicity due to high affinity or weak specificity, respectively. Treatment toxicity spectrums vary greatly even in patients with the same type of cancer. Common toxicities are fevers, chills, diarrhea colitis, maculopapular rash, hepatitis, and hormone gland disorder; therefore, routine monitoring of thyroid function, liver function, renal function, and complete blood count are absolutely necessary once treatment begins. Some side effects are reversible, and can be processed through the standard medicines. However, serious toxicities are lethal, which should be frequently followed-up, identified at an early stage and immediately symptomatic treated by high-dose immunosuppressors. In this case, thereafter, the same agent should not be challenged again.

scholarly journals OVARIAN CANCER;

2013 ◽  
Vol 20 (06) ◽  
pp. 904-908
Author(s):  
NASEER AHMED SHAIKH ◽  
RUKHSANA PARVEEN SAMO ◽  
M. QASIM MEMON
Keyword(s):  
Tumor Marker ◽  
Malignant Tumors ◽  
Germ Cell Tumors ◽  
Specific Treatment ◽  
Serum Levels ◽  
Ca 125 ◽  
Serum Tumor Marker ◽  
Serous Cystadenocarcinoma ◽  
Appropriate Therapy ◽  
Sex Cord Stromal Tumors

Object: 1). To analyze of serum tumor marker CA-125 in patients with ovarian malignant tumors. 2). To correlate betweenthe serum levels of tumor marker with histological types of ovarian malignant tumors. Study Design: Institution based descriptive andprospective study. Place & Duration: Department of Pathology, Liaquat University of Medical & Health Sciences, Jamshoro from January2009 to June 2011. Material & Methods: One hundred cases, diagnosed as ovarian malignant tumor on H&E staining were selected forstudy & measure serum CA-125 preoperatively and postoperatively in each case. Results: Out of 100 cases diagnosed as on H&E stainwere 33 serous cystadenocarcinoma, 24 mucinous adenocarcinoma, 10 germ cell tumors and 08 sex-cord stromal tumors. On serumanalysis increased level of CA-125 was seen preoperatively in 33/33 cases of serous cystadenocarcinoma and 24/29 cases of mucinousadenocarcinoma. Serum tumor marker value was declined following appropriate therapy of the tumors. Conclusions: Serum tumormarkers CA-125 is useful and important for the detection of ovarian tumors. It is most significant for serous cystadenocarcinoma. It mayalso help in prognosis and specific treatment of ovarian malignancies relating to histological type.

scholarly journals Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis

2018 ◽  
Vol 26 (3) ◽  
pp. 515-518
Author(s):  
Mehmet Sitki Copur ◽  
Julie Marie Wurdeman ◽  
Debra Nelson ◽  
Ryan Ramaekers ◽  
Dron Gauchan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pulmonary Fibrosis ◽  
Lung Transplantation ◽  
Tumor Marker ◽  
Tumor Markers ◽  
Early Stage ◽  
Serum Tumor Marker ◽  
Normal Range ◽  
Bilateral Lung Transplantation ◽  
Bilateral Lung

Solid tumors involving glandular organs express mucin glycoprotein that is eventually shed into the circulation. As a result, these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA27-29 and CA15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines do not recommend the use of tumor markers for routine surveillance of early stage disease but recognize their utility in the metastatic setting. We present a patient with stage IIIA breast cancer and preexisting hypersensitivity pneumonitis who was found to have an elevated serum tumor marker CA27-29. After successful curative intent treatment of her early stage breast cancer, she developed gradual and progressive worsening of her lung disease with eventual development of severe pulmonary fibrosis requiring bilateral lung transplantation. As part of the pretransplant evaluation, she was found to have an elevation of serum tumor marker CA27-29. While the diagnostic evaluation, including imaging studies, was negative for the presence of recurrent disease, the serial serum tumor marker CA27-29 levels remained persistently elevated. The decision was made for her to undergo bilateral lung transplantation. Shortly after surgery, her CA27-29 tumor marker level returned to normal range, and it has continued to remain in the normal range with no evidence of breast cancer recurrence.

scholarly journals Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Wenjing Li ◽  
Zhumei Cui ◽  
Yan Kong ◽  
Xiangyu Liu ◽  
Xiangyu Wang
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Significance ◽  
Ovarian Tumor ◽  
Tumor Staging ◽  
Serum Levels ◽  
Clinicopathological Characteristics ◽  
Chemotherapy Response ◽  
Healthy Women ◽  
Benign Ovarian Tumor

Objective. To investigate the serum levels of calgizzarin (S100A11) and matrix metalloproteinase-9 (MMP9) in patients with epithelial ovarian cancer (EOC) and determine their clinical significance. Methods. Serum levels of S100A11 and MMP9 were detected in patients with EOC, patients with benign ovarian tumor, and healthy women. The correlation between the two markers and clinicopathological characteristics of ovarian cancer was analysed. Results. The serum levels of S100A11 and MMP-9 in patients with EOC were higher than those in patients with benign ovarian tumor and in healthy women, and the expression levels of S100A11 and MMP-9 were positively correlated. S100A11 and MMP-9 were correlated with tumor staging, postoperative residual foci, ascites volume, serum CA125 level, chemotherapy response, and lymph node metastasis, while S100A11 and MMP-9 were not associated with the bilevel classification, histological type, age, and degree of differentiation. Conclusion. S100A11 and MMP-9 were both highly expressed in the serum of patients with EOC and were associated with cancer development, invasion, and metastasis. Therefore, they can be used as an important reference maker in the diagnosis and treatment of ovarian cancer.

scholarly journals Disappearance Curves for Tumor Markers after Resection of Intrathoracic Malignancies

1999 ◽  
Vol 14 (2) ◽  
pp. 99-105 ◽  
Author(s):  
T. Yoshimasu ◽  
S. Maebeya ◽  
T. Suzuma ◽  
T. Bessho ◽  
H. Tanino ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Residual Tumor ◽  
Serum Levels ◽  
Least Square ◽  
Serum Tumor Marker ◽  
Elimination Kinetics ◽  
Linear Least Square ◽  
Kinetics Of

Determination of the standard elimination kinetics of tumor markers will be helpful in the diagnosis of malignancies. We analyzed the disappearance curves for serum tumor marker levels after resection of intrathoracic malignancies. Serum levels of CEA, SLX, AFP, CA 19-9, SCC, TPA and CYFRA were measured several times after surgery in a total of 40 patients. To obtain precise biological half-lives, we applied non-linear least square analysis, taking into consideration the possibility of residual tumor cells. Disappearance curves were monophasic for CEA, SCC, TPA, CYFRA and SLX and biphasic for CA 19-9 and AFP. Temporary elevation of serum levels after surgery was observed for SCC, TPA and CYFRA. The average half-lives of CEA, SLX, SCC, TPA and CYFRA were 1.5 days, 2.7 days, 2.2 hours, 2.5 hours and 1.5 hours, respectively. The average half-life of CA 19-9 was 0.5 days in the first compartment and 4.3 days in the second compartment, while that of AFP was 1.0 days and 6.3 days, respectively. These values will be helpful in the interpretation of serum tumor marker levels after surgery.

Sign in / Sign up

Export Citation Format

Share Document